The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer

被引:2
|
作者
Levine, Jonah M. [1 ,2 ]
Rompen, Ingmar F. [1 ,2 ,3 ]
Franco, Jorge Campos [1 ,2 ]
Swett, Ben [1 ,2 ]
Kryschi, Maximilian C. [3 ]
Habib, Joseph R. [1 ,2 ]
Diskin, Brian [1 ,2 ]
Hewitt, D. Brock [1 ,2 ]
Sacks, Greg D. [1 ,2 ]
Kaplan, Brian [1 ,2 ]
Berman, Russel S. [1 ,2 ]
Cohen, Steven M. [1 ,2 ]
Wolfgang, Christopher L. [1 ,2 ]
Javed, Ammar A. [1 ,2 ]
机构
[1] NYU Grossman Sch Med, Dept Surg, 550 First Ave, New York, NY 10016 USA
[2] NYU Langone Hlth, New York, NY USA
[3] Heidelberg Univ Hosp, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany
关键词
Pancreatic ductal adenocarcinoma; Metastatic disease; Sites of metastasis; Extended survival; Pancreas; LIVER METASTASIS; PROGNOSTIC VALUE; TUMOR-CELLS; GEMCITABINE; RESECTION; SURGERY; TIME;
D O I
10.1016/j.pan.2024.06.004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background objectives: The aim of this study was to determine the role of site-specific metastatic patterns over time and assess factors associated with extended survival in metastatic PDAC. Half of all patients with pancreatic ductal adenocarcinoma (PDAC) present with metastatic disease. The site of metastasis plays a crucial role in clinical decision making due to its prognostic value. Methods: We examined 56,757 stage-IV PDAC patients from the National Cancer Database (2016-2019), categorizing them by metastatic site: multiple, liver, lung, brain, bone, carcinomatosis, or other. The sitespecific prognostic value was assessed using log-rank tests while time-varying effects were assessed by Aalen's linear hazards model. Factors associated with extended survival (>3years) were assessed with logistic regression. Results: Median overall survival (mOS) in patients with distant lymph node-only metastases (9.0 months) and lung-only metastases (8.1 months) was significantly longer than in patients with liver-only metastases (4.6 months, p < 0.001). However, after six months, the metastatic site lost prognostic value. Logistic regression identified extended survivors (3.6 %) as more likely to be younger, Hispanic, privately insured, Charlson-index <2, having received chemotherapy, or having undergone primary or distant site surgery (all p < 0.001). Conclusion: While synchronous liver metastases are associated with worse outcomes than lung-only and lymph node-only metastases, this predictive value is diminished after six months. Therefore, treatment decisions beyond this time should not primarily depend on the metastatic site. Extended survival is possible in a small subset of patients with favorable tumor biology and good conditional status, who are more likely to undergo aggressive therapies. (c) 2024 IAP and EPC. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:887 / 893
页数:7
相关论文
共 50 条
  • [1] Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients
    Lai, Gu-Shun
    Chen, Chuan-Shu
    Cheng, Jason Chia-Hsien
    Li, Jian-Ri
    Yang, Cheng-Kuang
    Lin, Chia-Yen
    Hung, Sheng-Chun
    Chiu, Kun-Yuan
    Wang, Shian-Shiang
    PLOS ONE, 2024, 19 (09):
  • [2] The impact of different metastatic patterns on survival in patients with pancreatic cancer
    He, Chaobin
    Huang, Xin
    Zhang, Yu
    Lin, Xiaojun
    Li, Shengping
    PANCREATOLOGY, 2021, 21 (03) : 556 - 563
  • [3] EXTENDED SURVIVAL AND REMISSION RATES IN METASTATIC BREAST CANCER
    VANDYK, JJ
    FALKSON, G
    CANCER, 1971, 27 (02) : 300 - &
  • [4] Survival rates in patients with metastatic spinal cancer
    Tatsui, H
    Onomura, T
    Morishita, S
    Oketa, M
    Inoue, T
    Abe, M
    XXX WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS, VOLS 1-2, 1996, : 1349 - 1352
  • [5] Locally advanced unresectable and metastatic pancreatic cancer predictors of survival
    Cipriano, A.
    Snores, A.
    Tavares, A.
    Iita, A. Mesc
    Sottomayor, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Predictors of survival in patients with refractory metastatic colorectal cancer
    Kim, S.
    Lee, H.
    Baek, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [7] Morphomics, Survival, and Metabolites in Patients With Metastatic Pancreatic Cancer
    Gunchick, Valerie
    Brown, Edward
    Liu, Juan
    Locasale, Jason W.
    Philip, Philip A.
    Wang, Stewart C.
    Su, Grace L.
    Sahai, Vaibhav
    JAMA NETWORK OPEN, 2024, 7 (10)
  • [8] Improvement in survival for patients with metastatic pancreatic cancer (PCa)
    Dobrila-Dintinjana, R
    Rubinic, M
    Kraus, I
    Uravic, M
    Ivanis, N
    Depolo, A
    Mustac, E
    Kovac, D
    Dintinjana, M
    EUROPEAN CONGRESS I.H.P.B.A. "BUDAPEST 1999", 1999, : 305 - 314
  • [9] Prognosticators of survival in patients with metastatic pancreatic cancer and ascites
    Berger, J. M.
    Alany, A.
    Berchtold, L.
    Puhr, R.
    Friedrich, A.
    Scheiner, B.
    Prager, G. W.
    Preusser, M.
    Berghoff, A. S.
    Bergen, E. S.
    ESMO OPEN, 2023, 8 (06)
  • [10] Metastatic sites and survival in lung cancer
    Riihimaeki, M.
    Hemminki, A.
    Fallah, M.
    Thomsen, H.
    Sundquist, K.
    Sundquist, J.
    Hemminki, K.
    LUNG CANCER, 2014, 86 (01) : 78 - 84